Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021736 · ClinicalTrials.gov registry record · Phase 2
Phase II/III Study of Anti-VEGF in Neovascular AMD
A Phase 2 study, sponsored by Eyetech Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 540
- Enrollment target
NCT00021736 is a Phase 2 study that has completed, run by Eyetech Pharmaceuticals. The registered enrollment target is 540 participants.
The verdict
NCT00021736, a Phase 2 study, has completed, sponsored by Eyetech Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 540 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether the anti-VEGF drug is effective at stabilizing and/or improving vision in patients with the wet form of AMD
Interventions
- DRUG EYE001 anti-VEGF aptamer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2001-07 |
| Est. Completion | 2002-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00021736
The ClinicalTrials.gov registry entry for NCT00021736 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 540 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eyetech Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EYE001 anti-VEGF aptamer is the first listed.
NCT00021736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00021736 about?
NCT00021736 is a clinical study titled "Phase II/III Study of Anti-VEGF in Neovascular AMD". The purpose of the study is to determine whether the anti-VEGF drug is effective at stabilizing and/or improving vision in patients with the wet form of AMD
What is the current status of trial NCT00021736?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 540 participants. The study started on 2001-07. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00021736?
The interventions under investigation include: EYE001 anti-VEGF aptamer (DRUG).
Who is sponsoring clinical trial NCT00021736?
This trial is sponsored by Eyetech Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.